The most underestimated category, and the one with the most long-term potential, is clinical-driven AI, where the model is ...

China Food and Drug Administration (CFDA) is facing increasing pressure as a backlog of pharmaceutical marketing and clinical trial applications grow, though trial standards there are approaching ...

By fine-tuning domain-specific models with real clinical operations data — such as historical performance, feasibility ...

Medical device innovation is laborious because of the high bar for validating that the technology does no harm. Patient recruitment for statistically powered trials stretches timelines and drives ...

By M. Marin OTCQB: AINMF READ THE FULL AINMF RESEARCH REPORT AINMF believes platform is well-positioned, as use of AI in clinical development is expected to rise NetraMark (OTCQB: AINMF), an AI ...

Despite rapid growth, only 9.2% of DCTs are multiregional and over 80% single-country, indicating challenges in international implementation. 2 With regulatory agencies 4–7 underscoring risk-based ...

The Biostatistics Unit at the Germans Trias i Pujol Research Institute (IGTP), in collaboration with researchers from several ...

Why does it take a new drug 10 years, on average, to come to market? Part of the reason lies in the dead time in the process. Historically, trials have required tedious tabulations and repeated ...

Carolina Carrasco, senior director at IQVIA, explores how fragmented financial workflows can create administrative burden and uncertainty for trial sites.